Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The volume has picked up with the price moving higher.
I watched AVXL trade today. I don't know what it is, but it was very different. I read most all posts on this board, and the posts seemed to me to match the mood of the AVXL stock activity. Although I don't know how to describe it, I was never uncomfortable with what I watched -- just the opposite. I am very long AVXL. All day long I felt a deep sense of peace, but I do not know why.
So true.
Although AVXL has been down, it appears that money flow persistency has been strong, money flow is beginning to pick up, insiders are buying (according to Chainkin), and relative strength versus the market looks promising. I believe we should see AVXL share price move up from here.
Thanks. I appreciate that.
Yes, maybe so, but I'm opting out. If all shareholders opted out, it would gut the class action. I know that it will not happen, but I'm opting out, and I feel good about doing that.
Option to opt out of class. According to the complaint, potential members of the class are all persons, other than defendants, who purchased or acquired shares of AVXL during the period of May 17, 2013 - December 28, 2015. A notice will be sent to these shareholders giving them, including me, an opportunity to opt out of the class. If such a shareholder does not opt out, they are included in the class. Timely notice must be given to class counsel and the Court if a person desires to opt out. Any person that opts out will not be part of the class, will not be represented by class counsel, and will not in any way be bound by or participate in this litigation. I purchased all of my AVXL shares during the class period. I plan to opt out of the class.
Excellent, George. A scientific basis for Anavex therapy to be used to treat many diseases besides Alzheimer's, Parkinson's, etc.
Yes, as it is said: "The wheels of justice grind slowly". However, Xena and others are correct in that the lawsuits lack merit. Quoting from internet articles is easy, but that is not evidence any more than if I published an article that said just the opposite. And, yes there will be a motion to dismiss filed by Anavex, which I believe will be successful if no other factual basis for the suit exists other than what he said/she said. Further, the facts must be relevant to Anavex as it exists today. Facts from the past about the shell company and its previous officers/directors are totally irrelevant.
I agree completely and add this: Biotech has been volatile over the past year the past year or so because of the political uproar associated with soaring drug costs. This volatility was spurred by comments by the head of the FDA and some presidential candidates, which will soon be forgotten. This has resulted in the average investor running to dump their biotech shares. On the other hand, this is when these stocks go on sale, and a time when the better investors make bigger additons. Biotech and Healthcare stocks are where the big additions will be made. Also, with share prices beaten down, I think there will be more mergers and acquisitions.
Receipt of a subpoena means nothing other than that the SEC is conducting an investigation. Witnesses (innocent parties), naturally or obviously, receive subpoenas in instances like this to enble the SEC to obtain information about unusual stock activity. We all know that the activity of Anavex stock has been very unusual -- that is what everyone on this board has been constantly posting about (manipulation of AVXL stock). Many of us believe that this manipulation involves naked shorting, for example. Anavex's records are certainly needed to do a complete and thorough investigation.
SEC investigations are generally confidential.
If the SEC makes a preliminary determination to recommend emforcement action, it may provide a notice informing the target of the investigation of the proposed charges and the target can then voluntary set forth their position. Otherwise, the investigation by the SEC is confidential.
I believe that third parties (not the Anavec corporate entity) are being investigated, but the SEC investigation of those parties is confidential. Therefore, Anavex (nor anyone else) knows what the SEC is investigation. I do not believe that Anavex is the target. If it were the target, it would know. Keep in mind too that this is simply an investigation, and it may result in no SEC action whatsoever. My best guess is that this may be an investigation of naked shorts. Now, ask yourself: What is most likely being investigated? If you conclude it is most likely naked shorting, who is it that may be doing this naked shorting? Someone like GS or someone like Missling?
One thing for sure: All the negative comments about Anavex have not been for or about benefiting science, patients suffering from disease, Anavex shareholders, or the advancement of society in general. Notice how frequent, repetitive, aggressive, and antagonistic the attacks have been. These assaults result from an intense and selfish desire to gain a profit or advantage. We should not let these greedy people control our minds or emotions, although their efforts will continue as long as they feel they can profit.
Alzheimer's disease is supposed to be mentioned in the State of the Union address tonight.
I am happy for you and your family. I can stand to lose the money I have invested in Anavex although I have no desire for that to happen. I can move on with my life and live to fight another day. However, I would be very sorry if there is no improvement or cure. Thank you for sharing this.
Bad news now or in the immediate future would be surprising. We received good news yesterday. I do not know when Anavex elected to attend the investment conference in NY in February. If that was decided recently, as opposed to attending the conference in San Francisco, it may indicate that Anavex is not attending with the expectation of presenting negative information.
Yes, a very good point. I read the announcement to say there was no decline as would otherwise have been. Instead there was a 2 point improvement.
The 2 point improvement in MMSE seems very significant to me:
The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia. On average, the MMSE score of a person with Alzheimer's declines about two to four points each year.
The 2 point seems very significant to me:
The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia. On average, the MMSE score of a person with Alzheimer's declines about two to four points each year.
Anavex has been under attack, but its drug therapy, the company, Missling, the small AVXL staff, the science, the scientific board, the patent applications and the patent issuance are all real.
We all know drugs that target amyloid are not working, and it is likely amyloid is not the AZ culprit. Evidence that oxidation/nitration/inflammation is the cause of AZ exists. All of the science behind the development of AVXL therapy may be independently verified. On the other hand, those that attack Anavex avoid discussion of this science as well as discussion that amyloid target therapy is not working.
Missling and his small company staff have done nothing nefarious. The SEC subpoena issue is a red herring as I and others on this board have previously discussed. See my post # 476443 above dated December 31, 2015, for example. See the posts today by IQMike.
The adverse SA articles demonstrate nothing of substance about Anavex as it exists today. They turn away from discussing the science. Instead, they criticize the company because it came from a public shell or they attempt to discredit some third party such as Dr. Dee and use guilt by association tactics.
Jim Cramer, not a fan of mine, said something on NBC News the other night when asked about the stock market declines we have seen this week. His response: “Investors should never panic. There has never been a penny made by panicking.”
If you want to make real money, you should not do what everyone else is doing and follow the herd. Do not worry about simply looking bad. If you worry about that, you will never buy and stick with enough of something that works for it to make much of a difference for the better. Do your DD and do not invest more than you can afford to lose. Do not use margin.
I believe that real money, however, may be made by investing in something that is revolutionary in contrast to what everyone else has invested. AVXL engaged in development of a badly needed drug therapy that may revolutionize the treatment or cure of dreaded diseases that afflict our aging population and that is a huge market that is its focus. It is coming along at a time too when the world is grappling with containing escalating health care costs, and governments around the world need to cut spending to deal with their debt burdens.
Anything can fail or succeed. We will have our setbacks, but there are many reasons to believe that Anavex 2-73 (and other Anavex drug therapy) works. The adverse articles we have seen do not scientifically demonstrate that Anavex therapy does not work. The purpose of the clinical trails is to prove that this therapy works. It is up to the clinical trials and the FDA to make the determinations that this drug is safe, it has efficacy, and that it should be approved in the U. S.
Additionally, it may be more easily approved in foreign countries such as Japan, Australia, Israel, Canada and other countries. Lastly, if the drug is approved in any of the aforementioned countries it may be granted reciprocity in the U.S. if this law introduced in Congress passes: “Reciprocity Ensures Streamlined Use of Lifesaving Treatments ACT (S. 2388) or the RESULT ACT is passed by the U. S. Congress.
Stay focused, ignore the noise, do not panic, and give Anavex some time to prove itself!
Yes. That is natural. Although times like today and recent days have been uncomfortable, I try to focus on and remember the facts. I have a severe hearing problem, and I compare it to training to hear in noise by focusing on the speaker/message and ignoring the noise. The SA articles and securities lawsuits are noise - that's all!
Eaisi makes donepezil. Keep that in mind.
FOR IMMEDIATE RELEASE
September 19, 2014
For Print [PDF 63KB]
ARICEPT® APPROVED IN JAPAN AS TREATMENT FOR DEMENTIA WITH LEWY BODIES
WORLD'S FIRST TREATMENT FOR BOTH ALZHEIMER'S DISEASE AND DEMENTIA WITH LEWY BODIES
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its anti-Alzheimer's agent Aricept® (donepezil hydrochloride) has received approval for a new indication for dementia with Lewy bodies (DLB) in Japan. This marks the first time a treatment has been approved for DLB anywhere in the world.
Securities lawsuits are a dime a dozen. Yes, even Gilead was a target. So what? See this, for example:
November 18 2003
Company: Gilead Sciences, Inc.
Ticker Symbol: NASD: GILD
Class Period: July 14, 2003 to October 28, 2003
Court: Northern District, CA
Date Filed: Nov-17-03
Lead Plaintiff Deadline: Jan-12-04
Allegations:
A class action lawsuit has been filed in the United States District Court for the Northern District of California, civil action number C-03-4999, on behalf of all persons or entities who purchased or otherwise acquired Gilead Sciences, Inc. ("Gilead" or the "Company") securities (Nasdaq:GILD) during the class period: July 14, 2003 and October 28, 2003, inclusive. The Complaint names Gilead Sciences, Inc., John C. Martin, John F. Milligan, Mark L. Perry, Norbert W. Bischofberger, Anthony Carraciolo, and William A. Lee as defendants.
The Complaint alleges that Gilead and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the SEC. The Complaint further alleges that, in a scheme to allow Gilead insiders to sell their Gilead stock at artificially inflated prices, the defendants falsely represented that the strength of its sales of Viread (Gilead's HIV drug), during the second quarter of 2003. Defendants maintained that the strong sales numbers were due to an increase in prescriptions and not, as some analysts had cautioned, due to inventory build-up by distributors stocking up ahead of a price increase.
Such statements were materially false and misleading because, as defendants knew or recklessly disregarded, a material portion of the second quarter Viread sales were attributable to distributors stocking up ahead of a price increase. Gilead insiders sold a total of 303,981 shares in August 2003, reaping gross proceeds of $19,365,998, due to the artificially inflated prices. Gilead announced on October 28, 2003 that sales of Viread in the third quarter of 2003 would be materially less than expected because distributors would meet end-user demand for Viread by selling off overstock they accumulated in the second quarter. After the announcement and in reaction to it, the price of Gilead common stock plummeted, falling $7.46 in one day, from a close of $59.46 per share on October 28, 2003 to $52 per share on October 29, 2003. Maybe it's your stockbroker If you acquired the securities of the defendants during the Class Period you may, no later than Jan-12-04, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
Thanks, Hooperg83, for this sound and sensible perspective.
Everyone, let's not be victims to the age old maddening crowd psychology that Davis and others are playing around with to attempt to spook everyone to dump their shares. Do not let these actors control you mind and emotions. Let's keep our heads although some may lose theirs.
Me too! Holding!
Well, I take your word for it, and I am impressed. I think you did the right thing, and I wish you the best of luck!
I agree, and I believe that it is highly unlikely to have any significant future impact.
I think I noticed the other day that SEC Compliance is one of the sponsors or participants relative to the upcoming San Francisco January 11 conference where AVXL is to present?
Powerwalker: Thank you. I did not know that about Solanezumab.
I don't think it is that simple. Solanezmab, Lily's drug for example, undergoing clinical trials is covered by patents. If
solanezumab receives marketing authorization, PDL will receive a patent royalty of three percent for product manufactured and/or sold in the United States before expiration of Queen et al. patents and a two percent know-how royalty on worldwide sales for 12.5 years from date of first commercial sale. Why would big pharma, like Lily and others, want Anavex to succeed when they are seeking FDA approval for other amyloid type drugs covered by patents?
Likewise, see the Biogen clinical trials for its drug covered by patents.
Yes, besides Aricept, for example:Exelon, Razadyne, Cognex) and memantine (Namenda). And, look at what was done to extend the Namenda type of monopoly by attempting to switch the market for that drug to a newer, more expensive version. See this: http://www.wsj.com/articles/actavis-must-keep-selling-old-version-of-alzheimers-drug-namenda-court-rules-1432326861
Makemydaze: Thank you for the new article.
''Regarding the potential of ANAVEX 2-73, while I am no scientist leading experts are saying that Eli Lilly and Biogen may have the science all wrong and that AVXL has it correct. The drugs from Eli Lilly and Biogen are just antibodies against amyloid. In all likelihood, amyloid is not the cause of Alzheimer’s. Instead, Alzheimer’s is caused by oxidation and nitration. This is what ANAVEX 2-73 targets!! It’s a completely new approach to treating Alzheimer’s and that makes it so revolutionary. With anything this revolutionary, you will get conventional scientists coming out and bashing the new science. This is what is happening with AVXL because AVXL is disputing the conventional wisdom.
The funny thing with AVXL is that when the bears are given the facts of the science, they turn to their favorite tactic. They criticize the company because it came public via a shell. Well, when you have a drug that goes against the tide, traditional venture capitalists do not want to take this type of risk. They don’t want to go up against Eli Lilly and Biogen because they are in business with the big drug companies. The big drug companies don’t want AVXL to succeed. They want it to fail!''
The above quote from this article gets to the root of what is going on with this new scientific approach by Anavex to treat AZ. Remember, that scientists who come up with new discoveries have been persecuted throughout history. Galileo, for example, was persecuted in 1633 for publishing a treatise on his observation that the earth revolves around the sun. Revolutionary new discoveries go against established theories and beliefs. And yes, there is a huge amount of money at stake. Big pharma companies do not desire that their billion dollar monopolies on drugs that do not work to be damaged. It would be heart warming, however, for one of the big pharma companies to step up and say we put the patient first -- not our bottom line --. We are willing to take a chance to see if Anavex 2-73 works!
Enjoy your trip. As someone on the board said, the lawsuits are at this point nothing more than a fishing expedition. Additionally, I this is one of my posts from earlier today:
The truth about subpoenas and securities law suits. Companies that have done absolutely nothing wrong very often receive subpoenas to obtain information about legal proceedings against other unrelated parties. In fact, companies that are cooperating with the party bringing the proceeding request a subpoena first for very good reasons like giving the appearance of being independent, non-biased, confidentiality, etc.
Securities class action lawyers in an attempt to obtain potential cases run adds announcing investigations (NOT BECAUSE THEY THEN KNOW OF ANY OFFENSE) as a means of solicitation and as an attempt to be first in case something appearing actionable might surface. The do this TO OBTAIN A LEAD POSITION IN CASE SOMETHING ACTIONABLE MIGHT SURFACE. THEY ATTEMPT TO BE LEAD COUNSEL OR ON A COMMITTEE WITH LEAD COUNSEL TO CONTROL LITIGATION AND EARN MOST OF THE FEES IF SUCCESSFUL in any case that MAY arise out of the investigation. This "something" might be in relation to some party other than the party receiving the subpoena. Many times even if early lawsuits are filed the suits are dismissed because they have no merit.
If the government really had some real evidence that Anavex had done something wrong, the government would not have served a subpoena. Serving a subpoena on a wrong doer gives that wrong doer an opportunity to destroy or spoil the evidence. The government would have obtained a warrant and seized information from the company.
Therefore, I believe all odds are that this subpoena issue is not the about Anavex corporate entity itself. The truth is that no one on this board knows what it is about. The "investigating" lawyers know nothing about it. The FBI and/or the SEC are not going to disclose anything at this point. It is likely about an investigation of some unknown party -- not the Anavex corporate entity. I believe those that raise the subpoena issue against the company are simply red flag waiving. The subpoena issue is a red herring.
Exactly, a fishing expedition is the perfect expression to sum it all up. The lawsuits at this point are nothing more than fishing expeditions.
That is the lead counsel motion deadline date -- February 29. This firm, like all other plaintiff firms that file, hope to land a big shareholder to file as a class representative so the law firm may then have a shot at obtaining appointment lead counsel or co-lead counsel status. Lead counsel that is appointed by the court controls/runs the plaintiff side of the plaintiff side of the case. Lead counsel status pays off if the case that is filed is successful - more clout, more fees, etc. In my opinion, this case on file is extremely preliminary, and it may very well prove to be without merit, unsuccessful and/or much ado about nothing. Law firms that are the first to file have a better shot at lead the counsel position. These firms are prone to shoot first and find out later whether they have a case or not.
I remain long, and I have added shares today.
The truth about subpoenas and securities law suits. Companies that have done absolutely nothing wrong very often receive subpoenas to obtain information about legal proceedings against other unrelated parties. In fact, companies that are cooperating with the party bringing the proceeding request a subpoena first for very good reasons like giving the appearance of being independent, non-biased, confidentiality, etc.
Securities class action lawyers in an attempt to obtain potential cases run adds announcing investigations (NOT BECAUSE THEY THEN KNOW OF ANY OFFENSE) as a means of solicitation and as an attempt to be first in case something appearing actionable might surface. The do this TO OBTAIN A LEAD POSITION IN CASE SOMETHING ACTIONABLE MIGHT SURFACE. THEY ATTEMPT TO BE LEAD COUNSEL OR ON A COMMITTEE WITH LEAD COUNSEL TO CONTROL LITIGATION AND EARN MOST OF THE FEES IF SUCCESSFUL in any case that MAY arise out of the investigation. This "something" might be in relation to some party other than the party receiving the subpoena. Many times even if early lawsuits are filed the suits are dismissed because they have no merit.
If the government really had some real evidence that Anavex had done something wrong, the government would not have served a subpoena. Serving a subpoena on a wrong doer gives that wrong doer an opportunity to destroy or spoil the evidence. The government would have obtained a warrant and seized information from the company.
Therefore, I believe all odds are that this subpoena issue is not the about Anavex corporate entity itself. The truth is that no one on this board knows what it is about. The "investigating" lawyers know nothing about it. The FBI and/or the SEC are not going to disclose anything at this point. It is likely about an investigation of some unknown party -- not the Anavex corporate entity. I believe those that raise the subpoena issue against the company are simply red flag waiving. The subpoena issue is a red herring.
Anavex SEC Subpoena Likely a Red Herring. Read this.
http://www.barrons.com/articles/anavex-sec-subpoena-likely-a-red-herring-1451480511
Anavex SEC Subpoena Likely a Red Herring. See the below linked article from Barrons.
http://www.barrons.com/articles/anavex-sec-subpoena-likely-a-red-herring-1451480511
Your response clearly shows that you do not know that your statement is true. It would be easy for you to provide a basis for your belief.
It is a repetitive, inflammatory, baseless (having no relation to the company as it exists today) and insignificant article with no redeeming value, socially or financially. Ignore it.
You really should think in terms of "monopoly". One of the few ways to have a legal monopoly is to have a patent or patents on the product. Whatever is covered by valid and enforceable patents creates exclusive rights (monopolies) to sell those products for the duration of the patent(s). Otherwise, monopolies are illegal - in violation of the antitrust laws. The patent monopoly is what creates the value of the products. Whatever is not covered by valid and enforceable patents may be copied and sold by anyone. For example, when a brand name drug goes off patent and is copied by multiple generic companies, the price of the molecule covered by the brand name drug 's patent immediately plummets around 80% or more. Therefore, Anavex seeks multiple patents that are as broad as possible. That is what we shareholders desire, right? As many patents as is possible and that are as broad as possible.
It seems that even without Anavex obtaining a patent on the combination of AVXL 2-73 and donepezil (if AVXL is approved by the FDA), AVXL 2-73 may be prescribed as an add on therapy to donepezil. Of course, it is much more valuable for Anavex though to have a patent on the combination of 2-73 and donepezil to be administered in one pill rather than the two drugs to be taken separately. These are some reasons, I think:
1. Patient compliance, although CBD points out that this may not be a big deal. It's easier to administer one pill than 2. Dosage is more likely to be correct, etc. Plus, patients may forget to take one pill or take more than one when they should take only one of each.
2. Patent life (monopoly) may be extended as IP points out.
3. Another company may apply for some other combinations of AD drugs, and multiple patents by Anavex may block them if combination patents, methods of use patents are obtained by Anavex.(a patent person may better address this).
4. Its always better to have multiple patents to enforce. If enforcement fails on one, one of the others may succeed.